The schizophrenia patient population is gradually being recognized because of its high prevalence of cardiovascular, cerebrovascular and metabolic diseases, which are becoming more and more prominent. There are more and more cases of obesity, glucolipid metabolism in schizophrenia patients, the emergence of concurrent evidence due to diabetes, hypoglycemia, and sudden death. Causes of metabolic abnormalities in schizophrenia patients: related to their own genes. Receiving medication, lifestyle changes in patients, reduced outdoor exercise/work can increase their metabolic changes. The medications themselves (e.g., multi-receptor drugs) promote metabolic abnormalities. The three factors promote each other and the incidence of their metabolic syndrome is 2 to 3 times higher than normal.